Ophthalmic Infections

  1. Al-Badriyeh D, Leung L, Davies GE, et al.  Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin.  Ann Pharmacother 2009;43:1139-42.
  2. Al-Badriyeh D, Leung L, Davies GE, et al.  Successful use of topical voriconazole 1% alone as first-line antifungal therapy against Candida albicans keratitis.  Ann Pharmacother 2009;43:2103-7.
  3. American Academy of Ophthalmology Cornea/External Disease Panel.  Preferred Practice Pattern® Development Process and Participants.  Blepharitis Preferred Practice Pattern.  San Francisco, CA:  American Academy of Ophthalmology; 2018.  Available at https://doi.org/10.1016/j.ophtha.2018.10.019.
  4. American Academy of Ophthalmology Cornea/External Disease Panel.  Preferred Practice Pattern® Guidelines.  Bacterial Keratitis.  San Francisco, CA:  American Academy of Ophthalmology; 2013.  Available at www.aao.org/ppp.
  5. Auran JD, Starr MB, Jakobiec FA.  Acanthamoeba keratitis: a review of the literature.  Cornea 1987;6:2-26.
  6. Bacon AS, Frazer DG, Dart JKG, et al.  A review of 72 consecutive cases of Acanthamoeba keratitis, 1984-1992.  Eye 1993;7:719-25.
  7. Barron BA et al: Herpetic eye disease study group, a controlled trail of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 1994;101:1871-82.
  8. Baum J. Infections of the eye. Clin Infect Dis 1995;21:479-86.
  9. Beers M, Berkow R. The Merck manual of diagnosis and therapy 17th ed. West Point, PA: Merck & Co. Inc;1999:704-19.
  10. Berger ST, Mondino BJ, Hoft RH, et al.  Successful medical management of Acanthamoeba keratitis.  Am J Ophthalmol 1990;110:395-403.
  11. Boruchoff A, Boruchoff S.  Infections of the lacrimal system.  Infect Dis Clin N Am 1992;6:925-32.
  12. Callegan MC, Engelbert M, Parke II DW, et al.  Bacterial endophthalmitis:  epidemiology, therapeutics, and bacterium-host interactions.  Clin Micro Rev 2002;15:111-24.
  13. Donahue S, Khoury J, Kowalski R. Common ocular infections. A prescriber’s guide. Drugs 1996:52:526-40.
  14. Durand ML, Barshak MB, Sobrin L.  Eye infections.  N Engl J Med 2023;389:2363-75.
  15. Durand ML, Barshak MB, Sobrin L.  Eye infections - supplementary appendix.  N Engl J Med 2023;389:2363-75 DOI:
    10.1056/NEJMra2216081.
  16. Elder MJ, Dart JKG.  Chemotherapy for Acanthamoeba keratitis.  Lancet 1995;345:791-3.
  17. Fanella S, Singer A, Embree J.  Presentation and management of pediatric orbital cellulitis.  Can J Infect Dis Med Microbiol 2011;22:97-100.
  18. Friesen A. Sight for sore eyes. Pharm Pract 1997;13:71-78.
  19. Friesen AM.  Eyelid conditions: stye, chalazion and blepharitis, March 1, 2019 in CPS Minor Ailments, Canadian Pharmacists Association, 2021.
  20. Gilbert DN, Moellering RC, Eliopoulos GM, eds.  The Sanford guide to antimicrobial therapy 2012. Sperryville, VA:  Antimicrobial Therapy, Inc. 2012.
  21. Haimovici R, Roussel T. Treatment of gonococcal conjunctivitis with single intramuscular ceftriaxone. Am J Ophthalmol 1989;107:511-14.
  22. Hay J, Kirkness CM, Seal DV, et al.  Drug resistance and Acanthamoeba keratitis:  the quest for alternative antiprotozoal chemotherapy.  Eye 1994;8,555-63.
  23. Hershey B, Roth T. Orbital infections. Seminars in ultrasound, CT, and MRI 1997;18:448-59.
  24. Illingworth CD, Cook SD, Karabatsas CH, et al.  Acanthamoeba keratitis:  risk factors and outcome.  Brit J Ophthalmol 1995;79:1078-82.
  25. Kumar R, Lloyd D.  Recent advances in the treatment of Acanthamoeba keratitis.  Clin Infect Dis 2002;35:434-41.
  26. Larkin DFP, Kilvington S, Dart JKG.  Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide.  Ophthalmol 1992;99:185-91.
  27. Leal SM, Rodino KG, Fowler WC, et al.  Practical guidance for clinical microbiology laboratories: diagnosis of ocular infections.  Clin Microbiol Rev 2021;34(3):1-45.
  28. Leibowitz HM.  Primary care:  the red eye.  N Engl J Med 2000;343:345-51.
  29. Lindquist TD.  Treatment of Acanthamoeba keratitis.  Cornea 1998;17:11-16.
  30. Lupia T, Corcione S, Fea AM, et al.  Exogenous fungal endophthalmitis: clues to aspergillus aetiology with a pharmacological perspective.  Microorganisms 2021:9;74. https://doi.org/10.3390/microorganisms9010074
  31. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, et al.  Candida albicans endophthalmitis in brown heroin addicts:  response to early vitrectomy preceded and followed by antifungal therapy.  Clin Infect Dis 1998;27:1130-3.
  32. McCulley J, Dougherty J, Deneau D. Classification of chronic blepharitis. Ophthalmology 1982;89:1173-80.
  33. Moore DL, MacDonald NE; Canadian Pediatric Society, Infectious Diseases and Immunization Committee.  Preventing ophthalmia neonatorum.  Paediatr Child Health 2015;20:93-6.
  34. Mueller JB, McStay CM.  Ocular infection and inflammation.  Emerg Med Clin N Am 2008;26:57-72.
  35. Nageswaran S, Woods CR, Benjamin DK, et al.  Orbital cellulitis in children.  Pediatr Infect Dis J 2006;25:695-9.
  36. O’Brien T, Green W. Section M. Eye infections.  In:  Mandell GL, Douglas RG, Bennett JE, eds.  Principles and practice of infectious diseases. 4th ed. New York, NY: Churchill Livingstone;1995;1103-36.
  37. Pappas PG, Kauffman CA, Andes DR, et al.  Clinical practice guideline for the management of candidiasis. Clin Infect Dis 2016;62:1–50.
  38. Patterson TF, Thompson GR, Denning DW, et al.  Practice guidelines for the diagnosis and management of aspergillosis. Clin Infect Dis 2016:1-60 DOI: 10.1093/cid/ciw326
  39. Peek MJ, Bajoria R, et al.  Chemotherapy for acanthamoeba keratitis.  Lancet 1995;345:
  40. Pettit T, Holland G. Chronic keratoconjunctivitis associated with ocular adenovirus infection. Am J Ophthalmol 1979;88:748-51.
  41. Peyman G, Bassili S. A practical guideline for management of endophthalmitis. Ophthalmic Surg 1995;26:294-303.
  42. Pierre-Yves R, Adenis JP.  Comparative review of topical ophthalmic antibacterial preparations. Drugs 2001;61:175-85.
  43. Putnam CM.  Diagnosis and management of blepharitis: an optometrist’s perspective.  Clin Optometry 2016;8:71-8.
  44. Reese R, Betts R.  A practical approach to infectious diseases. 3rd ed. Boston/Toronto/London: Little, Brown and Company 1991;146-65.
  45. Riddell J, Comer GM, Kauffman CA.  Treatment of endogenous fungal endophthalmitis:  focus on new antifungal agents.  Clin Infect Dis 2011;52:648-53.
  46. Savla K, Le JT, Pucker AD.  Tea tree oil for Demodex blepharitis.  Cochrane Database of Systematic Reviews 2020, Issue 6. Art No.:  CD013333. DOI: 10.1002/14651858.CD013333.pub2.
  47. Seal DV, Hay J, Kirkness CM.  Chlorhexidine or polyhexamethylene biguanide for Acanthamoeba keratitis.  Lancet 1995;345:136.
  48. Seal DV, Hay J, Kirkness CM, et al.  Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine.  Eye 1996;10:413-21.
  49. Shtein RM.  Blepharitis.  Up-To-Date July 19, 2021.
  50. Spadea L, Giannico MI.  Diagnostic and management strategies of aspergillus endophthalmitis: current insights.  Clin Ophthalmol 2019:13;2573–82.
  51. Sunaric-Megevand G, Pournaras C. Current approach to postoperative endophthalmitis. Br J Ophthalmol 1997:81:1006-15.
  52. Tasman W, Jaeger E.  Duane’s Clinical Ophthalmology. Vol 4. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins;1998.
  53. Thomas PA, Geraldine P.  Infectious keratitis.  Curr Opin Infect Dis 2007;20:129-41.
  54. Virgil D, Liggett P.  Vitreoretinal surgery of the injured eye. Philadelphia, PA: Lippincott-Raven Publishers; 1999.
  55. Wang JC, Dahl AA.  Herpes simplex virus (HSV) keratitis treatment & management.  Medscape 2019. https://emedicine.medscape.com/article/1194268-treatment
  56. Wilhelmus K, et al: Herpetic eye disease study group, a controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994;101:1883-96.